Home » NICE Supports Servier’s Cancer Drug
NICE Supports Servier’s Cancer Drug
July 29, 2016
The UK’s drug pricing watchdog is recommending NHS reimburse for Servier’s metastatic colorectal cancer drug Lonsurf, provided the company offers the drug at a discounted price.
The UK’s National Institute for Health and Care Excellence’s decision marks the first positive appraisal of a third- or subsequent-line treatment for metastatic colorectal cancer, which often becomes resistant to therapies.
Upcoming Events
-
21Oct